top of page

Sublime MD Peptides Scam? đŸš©

  • Nov 4
  • 9 min read
sublime md homepage

COMPLETE SCAM WATCHING REPORT

Company Details: Sublime MD

Entity: Sublime MD / Sublime Medical Aesthetics & Dermatology (also operating under “Sublime Vitality”)

Lead physician / listed founder/leader: Dr. Ronnie N. Dawood, MD (Meet the Doctors page). sublimemd.com

Addresses:

26342 Oso Parkway, Suite 204, Mission Viejo, CA 92691. sublimemd.com

Main phone: (951) 222-2212 (Riverside). sublimemd.com

Other location phones: (909) 792-8600 (Redlands), (949) 367-1115 (Mission Viejo). sublimemd.com

Public email shown in social content: info@sublimemd.com 

Employees: 11-50 listed


Social Media:

Facebook: Sublime MD - Sublime Medical Aesthetics & Dermatology https://www.facebook.com/p/Sublime-MD-Sublime-Medical-Aesthetics-Dermatology-100037903764777/



Scam Score
Sublime md Peptides Lab Scam?đŸš©

A 1-star rating represents the lowest tier in our trust scale and signals high probability of deception, non-compliance, or consumer harm. Vendors in this category exhibit one or more of the following:


  • Verified false or misleading claims about origin, purity, or manufacturing.

  • Unverifiable lab documents (missing accreditation, self-issued, or forged).

  • Violations of federal or platform policies (FDA, FTC, Shopify, Stripe, etc.).

  • Mismatch between corporate filings, claimed experience, and public data.

  • Evidence of dosing/reconstitution instructions implying human use despite “research only” disclaimers.


Impact:

This low of a trust score automatically places the entity on ScamWatching.org red-flag statusÂ đŸš©â€” meaning the brand is considered untrustworthy until independently verified. Listings under this score are recommended for public exposure, platform reporting, and community alerting.



SUBLIME MD PEPTIDES GENERAL OVERVIEW

Sublime MD publicly presents itself as a dermatology and aesthetic clinic but simultaneously markets and distributes a broad range of unapproved injectable peptides through its linked brand, Sublime Vitality. The peptide catalog includes substances such as BPC-157, TB-500, MOTS-C, Melanotan II, GHK-Cu, HGH, IGF-1 LR3, Semaglutide, Tirzepatide, and Retatrutide—several of which are identified by the FDA as Category 2 high-risk compounds unsuitable for compounding or consumer sale.


The public evidence shows a consistent pattern of non-compliant and deceptive marketing behavior designed to create the appearance of medical legitimacy while avoiding pharmaceutical oversight.


SUMMARY ASSESSMENT

Sublime MD and its affiliate Sublime Vitality operate a high-risk peptide sales network using fabricated testimonials, unverified “third-party testing” claims, and unregistered compounding activities to promote unapproved injectable drugs for human consumption under the guise of medical aesthetics.


Primary risk vectors:


Unapproved Drug Distribution

  • Offers multiple FDA-flagged peptides for injection, listed with vial sizes and BAC water pairing.

  • No Certificates of Analysis, lot numbers, or lab verification links are provided.


False Quality and Compliance Claims

  • Asserts “Section 503A compliance” and “third-party testing,” yet there is no record of Sublime Vitality or Sublime MD on the FDA 503B Outsourcing Facility Registry or the California Board of Pharmacy’s licensed compounder list.

  • The firm’s operations—bulk orders and rapid fulfillment—contradict 503A’s patient-specific limitations.


Consumer-Directed Misbranding

  • The “Dr Skinny Shot” page advertises telemedicine weight-loss injections (Semaglutide, Tirzepatide, OzempicÂź, MounjaroÂź) and guarantees shipping within 48 hours.

  • These claims demonstrate patient-direct sales of prescription or compounded drugs without visible pharmacy registration.


PRODUCTS AND CLAIMS


Offerings: Full range of injectable peptides, including BPC-157, TB-500, GHK-Cu, MOTS-C, Melanotan II, GHRP-2, GHRP-6, CJC-1295, Ipamorelin, Tesamorelin, NADâș, IGF-1 LR3, HGH, Semaglutide, Tirzepatide, and Retatrutide. Catalog also features peptide “stacks” (BPC-157/TB-500 Blend, “Glow Protocol Blend”) paired with BAC water for reconstitution — marketed as ready-to-use vials rather than research reagents.


Claim Language: Therapeutic phrasing appears across pages — “supports recovery,” “enhances skin regeneration,” “improves metabolism and weight loss,” “promotes tissue healing,” and “delivers precision peptide therapy.” The copy repeatedly positions these peptides as patient-care solutions and practice-ready treatments, not laboratory materials.


Dosing Guides: No open “Dosing Guide” page is visible, but clinical dosing is embedded within product text (“reconstitute to precise concentrations tailored to each patient,” “includes 3 mL BAC water for easy mixing”). The Dr Skinny Shot page extends this to GLP-1 products, showing explicit mg strengths, weight-loss percentages, and shipping timelines, all characteristic of human-use dosing guidance.


Reconstitution Info: Listed directly in product descriptions — every peptide vial “paired with bacteriostatic water” and “reconstituted to precise concentrations.” This constitutes public instruction for injectable preparation and subcutaneous use.


Purity Claims: Every SKU references “third-party tested,” “lab tested,” “U.S. made,” or “RX-quality peptides.” No actual COAs, lab identifiers, or traceable certificates appear. The phrasing mirrors generic foreign-supplier marketing language (≄ 99 % purity claims without verification), suggesting unverifiable or imported testing data.


VIOLATIONS AND RED FLAGS

They repeatedly describe Sublime Vitality as a “US-based finisher of RX-quality peptides meeting Section 503A requirements,” but provide no FDA registration numbers, no CGMP or ISO-17025 certificates, no physical laboratory address, and no batch-level Certificates of Analysis.

FDA’s 503B Outsourcing Facility registry shows no listing for any “Sublime MD” or “Sublime Vitality.”

That absence, paired with marketing language such as “bulk order,” “rapid 48-hour fulfillment,” and “U.S. made and lab tested,” forms a classic red-flag combination indicating unregistered sterile production and deceptive quality claims. Sources: sublimemd.com / sublimevital.com


Therapeutic and Medical Claims

Public peptide catalog lists BPC-157, TB-500, GHK-Cu, MOTS-C, Melanotan II, PT-141, IGF-1 LR3, HGH, AOD-9604, CJC-1295, Ipamorelin, Tesamorelin, Semaglutide, Tirzepatide, and Retatrutide—each accompanied by strengths, dosing context, and “paired with BAC water” instructions.

Product blurbs use therapeutic disease-type language: “enhances recovery,” “improves metabolism,” “supports skin regeneration,” “reduces inflammation.” Those are structure/function and disease claims for substances that have no FDA approval, placing every listing squarely in “unapproved and misbranded drug” territory. Source: sublimemd.com/peptides-offered


sublime md peptides scam

Dosing and Distribution Conduct

Both Sublime MD and Sublime Vitality operate telemedicine-plus-shipping workflows.

The Dr Skinny Shot page promises “Prescribed in-office or online & shipped within 48 hours,” listing Ozempic¼, Mounjaroℱ, and generic Semaglutide/Tirzepatide.

Meanwhile, the peptide catalog promotes “personalized dosing” and “bulk orders for providers.”

That dual model—mass stock supply plus patient-direct shipment—violates 503A’s patient-specific limitation and functions as unregistered 503B-level distribution. Source: sublimemd.com / sublimevital.com


sublime md peptides scam

False Purity and Testing Assertions

Every SKU advertises “third-party tested for purity and sterility” and “lab verified ≄ 99 % purity.”

No public lab name, certificate number, or assay data appear anywhere on-site.

The wording mirrors generic foreign supplier templates, suggesting unverifiable import certificates rather than domestic analytical testing—another red flag for misbranding and adulteration.  Source: sublimevital.com


sublime md peptides scam

High-Risk Compounds and Category-2 Violations

The catalog includes peptides—BPC-157, Melanotan II, MOTS-C, TB-500—that the FDA designates as Category 2 bulk substances due to safety, impurity, and immunogenicity risks.

Compounding or distributing these for injection constitutes manufacturing of unapproved new drugs under 21 U.S.C. § 355 and § 352. Source: U.S. Food and Drug Administration


sublime md peptides scam


Deceptive Testimonials (Consumer Use Evidence)

The Sublime Vitality site hosts fake “customer recovery” reviews describing healing, weight-loss, and skin improvements after peptide use.

Such testimonials confirm intended human use, contradict the “not for human consumption” disclaimer in the footer, and qualify as misleading advertising and evidence of unapproved drug promotion.  Source: sublimevital.com


sublime md peptides scam


Regulatory Significance

Each of these behaviors—unapproved peptide claims, lack of COAs, unregistered sterile distribution, and consumer testimonials—mirrors patterns cited in FDA warning letters against peptide vendors marketing GLP-1 analogs and healing peptides. Taken together, Sublime MD / Sublime Vitality meet the threshold for unapproved drug manufacturing, misbranding, and deceptive marketing under the Federal Food, Drug, and Cosmetic Act.

sublime md peptides scam

Professional Licensing Conflict and Jeopardy for Unlawful Peptide Commerce


A verified National Provider Identifier (NPI #1851593065) confirms that Dr. Ronnie Nathan Dawood is an actively licensed physician in California, practicing internal medicine and dermatology at 26342 Oso Parkway Suite 204, Mission Viejo, CA 92691.This verification establishes that Sublime MD operates under a state-issued medical license, which carries explicit ethical and statutory obligations under California Business & Professions Code § 4170-4172 and 21 U.S.C. §§ 331, 352, 355.


Despite that licensure, Sublime MD / Sublime Vitality openly markets and distributes non-FDA-approved “research peptides” such as BPC-157, TB-500, Melanotan II, MOTS-C, and GHK-Cu, often described as “U.S. made and lab tested” but showing no traceable Certificates of Analysis or FDA-registered manufacturing source.

Multiple lot descriptions and phrasing patterns used on the Sublime Vitality site match foreign-supplier templates common to Chinese peptide exporters, suggesting that the materials being resold are imported research compounds, not products produced in a licensed U.S. facility.


Because Dr. Dawood and any affiliated clinicians hold active state medical licenses, their participation in the sale or distribution of imported research-grade peptides exposes those licenses to disciplinary action. Under California Medical Board regulations, a physician who prescribes, sells, or profits from unapproved foreign drug substances may be cited for “unprofessional conduct,” “distribution of adulterated or misbranded drugs,” and “gross negligence.” Such conduct can lead to license suspension, revocation, or mandatory probation if regulators determine the products originated from non-certified overseas suppliers or were represented as therapeutic without FDA clearance.


In effect, the use of an active medical license to market peptides sourced from China transforms a civil labeling violation into a professional-license offense. It directly conflicts with both FDA import regulations (21 CFR Part 1 Subpart E) and the California Medical Practice Act, which prohibit licensed practitioners from participating in the sale or promotion of unapproved foreign pharmaceuticals.


Pattern of Risk and Regulatory Evasion


The investigation into Sublime MD and its affiliated brand Sublime Vitality reveals a coordinated pattern of regulatory evasion, deceptive medical marketing, and potential misuse of active physician licenses. Although the organization presents itself as a “U.S.–based finisher of RX-quality peptides meeting Section 503A standards,” public records and site data point to unregistered manufacturing, unverifiable sourcing, and unapproved drug promotion.


Sublime MD operates a dual-infrastructure model—a clinical website (sublimemd.com) that advertises “prescribed and shipped” peptides and GLP-1 products, and a wholesale platform (sublimevital.com) offering “bulk ordering,” “2-day shipping,” and “third-party tested” peptide vials. This structure blurs the line between medical practice and unlicensed pharmaceutical distribution, allowing direct-to-consumer sales of non-FDA-approved peptides under a medical façade.


The peptide catalog lists a wide array of high-risk compounds—BPC-157, TB-500, MOTS-C, Melanotan II, GHK-Cu, PT-141, HGH, IGF-1 LR3, AOD-9604, and GLP-1 analogs (Semaglutide, Tirzepatide, Retatrutide)—each presented with dosing strengths, reconstitution language, and therapeutic claims such as “enhances recovery,” “improves metabolism,” and “restores youthful skin.” These are disease and structure/function claims for substances not approved for human use, thereby classifying them as unapproved and misbranded drugs under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §§ 331, 352, 355).


Further compounding the risk, the business employs a telemedicine + rapid-shipment workflow, promising prescription approval and delivery within 48 hours—an operational pattern consistent with 503B outsourcing behavior despite no FDA registration. This model violates 503A’s patient-specific limitations, exposing the clinic to enforcement for unregistered sterile production and improper distribution of compounded drugs.

Critically, the lead physician Dr. Ronnie Nathan Dawood (NPI # 1851593065) is a licensed California medical doctor, which introduces a deeper compliance breach. While this confirms professional status, it simultaneously imposes legal and ethical restrictions against the sale or resale of research-grade peptides, especially those imported from foreign suppliers.


The Sublime Vitality catalog mirrors Chinese peptide-export language (“99 % purity,” “lab tested,” “bulk available”), suggesting overseas sourcing and repackaging rather than FDA-regulated manufacture. Under California Medical Board and FDA statutes, participation by a licensed physician in the sale or promotion of unapproved foreign drugs constitutes unprofessional conduct—a disciplinary ground that can lead to license suspension or revocation.


In essence, Sublime MD and Sublime Vitality exhibit a dual pattern of violation:

  1. Regulatory deception through the marketing and sale of unapproved peptide drugs under false claims of U.S. manufacture and compounding compliance; and

  2. Professional licensing jeopardy by using an active medical license to legitimize and profit from imported “research peptides” outside lawful pharmaceutical channels.


Until verifiable COAs, FDA registrations, and state compounding licenses are publicly produced, Sublime MD’s peptide operations should be considered high-risk, non-compliant, and in violation of both federal drug law and state medical-licensure standards.


FDA Crackdown: Three Peptide Companies Cited for the Same Violations Seen at Sublime MD

Here are the top 3 companies that has been cited for the same violations seen at Sublime MD


 US Chem Labs (uschemlabs.com)

Warning Letter (Feb 7, 2024) Direct link to warning letter: U.S Food And Drug Administration

Site offered semaglutide, tirzepatide and thymalin to U.S. buyers; despite “research only/not for human consumption” labels, the overall marketing established intended human use. FDA called the products unapproved new drugs and misbranded (no adequate directions for use for laypeople)

GLP-1 Solution (glp1solution.store)

Warning Letter (Sept 9, 2025) Direct link to warning letter: U.S Food And Drug Administration

Offered retatrutide, semaglutide, tirzepatide as compounded drug products. FDA states retatrutide cannot be used under 503A or 503B conditions, so the firm’s products are unapproved and misbranded; the letter also details failures to meet 503A/503B conditions and labels with inadequate directions for use.

Veronvy (veronvy.com)

Warning Letter (Dec 10, 2024) Direct link to warning letter: U.S Food And Drug Administration

 Marketed “GLP-1” weight-loss drops to consumers, claiming “FDA approved” and making efficacy promises. FDA called them unapproved and misbranded drugs, flagging deceptive “FDA APPROVED” graphics and weight-loss claims. While these were oral drops rather than vials, the violation pattern is identical: human-use claims for non-approved products, misleading marketing, interstate sales.


 US Chem Labs  Warning Letter Highlighting their Violations:


sublime md peptides scam


GLP-1 Solution Warning Letter Highlighting their Violations:


sublime md peptides scam


Veronvy  Warning Letter Highlighting their Violations:


sublime md peptides scam


All findings and supporting evidence referenced in this report are sourced from publicly available records. Any attempt to alter or remove such material may constitute interference with public documentation and will be noted for compliance review.


Individuals who have experienced deceptive or unauthorized practices involving Alpha BioMed Labs are encouraged to file a report using our intake form for review and documentation. Submissions may be evaluated for potential escalation to a coordinated consumer complaint or class action proceeding if sufficient evidence is established.



Comments

bottom of page